CLVS - Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial

• Clovis Oncology ( NASDAQ: CLVS ) said Rubraca as initial maintenance therapy improved progression-free survival (PFS), compared to placebo across disease risk subgroups in patients with ovarian cancer.
• The company presented data from a subgroup analysis of a monotherapy comparison in the phase 3 trial called ATHENA at the European Society of Medical Oncology (ESMO) Congress 2022 in Paris.
• ATHENA-MONO enrolled 538 women with high-grade ovarian, fallopian tube or primary peritoneal cancer.
• Patients who received Rubraca as maintenance therapy showed PFS (length of time during/after therapy a patient lives with the disease without it getting worse) benefit regardless of surgical outcome, whether there was complete resection during cytoreductive surgery or not, the company said in a Sept. 11 press release.
• In addition, patients treated with Rubraca as maintenance therapy showed benefit among all subgroups when evaluated against response per RECIST v1.1 at any time during first-line chemotherapy.
• Clovis noted that in other subgroups based on baseline clinical characteristics, including FIGO stage, timing of surgery, and CA-125 levels, also showed that patients treated with Rubraca experienced a PFS benefit compared to those treated with placebo.
• CLVS +14.78% to $1.32 premarket Sept. 12

For further details see: